0
Original Contribution | ONLINE FIRST

Using Exome Sequencing to Reveal Mutations in TREM2 Presenting as a Frontotemporal Dementia–like Syndrome Without Bone Involvement ONLINE FIRST

Rita João Guerreiro, PhD; Ebba Lohmann, MD; José Miguel Brás, PhD; Jesse Raphael Gibbs, MS; Jonathan D. Rohrer, MRCP; Nicole Gurunlian, MS; Burcu Dursun, MD; Basar Bilgic, MD; Hasmet Hanagasi, MD; Hakan Gurvit, MD; Murat Emre, MD; Andrew Singleton, PhD; John Hardy, PhD
Arch Neurol. 2012;():1-7. doi:10.1001/archneurol.2013.579.
Text Size: A A A
Published online

Objective  To identify new genes and risk factors associated with frontotemporal dementia (FTD). Several genes and loci have been associated with different forms of FTD, but a large number of families with dementia do not harbor mutations in these genes.

Design  Whole-exome sequencing and whole-genome genotyping were performed in all patients. Genetic variants obtained from whole-exome sequencing were integrated with the data obtained from whole-genome genotyping.

Setting  Database of the Behavioral Neurology Outpatient Clinic of the Department of Neurology, Istanbul Faculty of Medicine, Istanbul, Turkey.

Patients  Forty-four Turkish patients with an FTD-like clinical diagnosis were included in the study. Relatives were screened when appropriate.

Main Outcome Measure  Mutations in the triggering receptor expressed on myeloid cells 2 gene (TREM2).

Results  In 3 probands with FTD-like disease, we identified different homozygous mutations in TREM2 that had previously been associated with polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL). None of these 3 patients had a typical clinical presentation of PLOSL: they presented with behavioral change and subsequent cognitive impairment and motor features but without any bone cysts or bone-associated phenotypes. Imaging showed white matter abnormalities as well as frontal atrophy in all 3 patients.

Conclusions  Our results show that TREM2 is responsible for an unexpectedly high number of dementia cases in our cohort, suggesting that this gene should be taken into account when mutations in other dementia genes are excluded. Even for complex syndromes such as dementia, exome sequencing has proven to be a rapid and cost-effective tool to identify genetic mutations, allowing for the association of clinical phenotypes with unexpected molecular underpinnings.

Figures in this Article

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

Figures

Place holder to copy figure label and caption
Grahic Jump Location

Figure 1. Pedigrees of the 3 families where triggering receptor expressed on myeloid cells 2 gene (TREM2) mutations were found. Arrowheads indicate probands. Black filled symbols represent affected subjects with dementia. White symbols represent unaffected family members and white symbols with a black dot represent individuals where dementia has been reported but not clinically confirmed. The genotypes (N indicates normal and M, mutation found) are represented for those individuals for whom DNA samples were available.

Place holder to copy figure label and caption
Grahic Jump Location

Figure 2. Magnetic resonance images from the proband of family 1. Sagittal T1-weighted (A), axial T2-weighted (B), and coronal T1-weighted (C) images show marked thinning of the corpus callosum; diffuse confluent white matter abnormalities in the periventricular white matter, especially adjacent to the anterior and posterior horns of the lateral ventricle; cortical atrophy; and disproportionally enlarged ventricles.

Place holder to copy figure label and caption
Grahic Jump Location

Figure 3. Magnetic resonance images from the proband of family 2. Sagittal T2-weighted (A), coronal T1-weighted (B), and axial fluid-attenuated inversion recovery–weighted (C) images show thinning of the corpus callosum with cortical atrophy and periventricular white matter abnormalities.

Place holder to copy figure label and caption
Grahic Jump Location

Figure 4. Magnetic resonance images from the proband of family 3. Sagittal T1-weighted (A), axial fluid-attenuated inversion recovery–weighted (B), and coronal T2-weighted (C) images reveal significant thinning of the corpus callosum; diffuse confluent white matter abnormalities in the periventricular white matter, especially adjacent to the anterior and posterior horns of the lateral ventricle; global cortical atrophy; and enlarged ventricles.

Place holder to copy figure label and caption
Grahic Jump Location

Figure 5. The triggering receptor expressed on myeloid cells 2 gene (TREM2) structure spans 41126246 to 41130922 base pairs (bp) on chromosome (chr) 6p21.1. A, Schematic of TREM2 (drawn using FancyGene19), the mutation nomenclature given with respect to RefSeq identifier NM_018965.2. Exons are drawn to scale and represented with gray boxes with untranslated regions (UTR) in red. Mutation locations are approximate: mutations identified in this study are represented below and previously described mutations are represented on top. B, The conservation of mutations identified in the present study. GenBank accession numbers: NP_061838.1, Homo sapiens ; XP_001174113.1, Pan troglodytes ; XP_851231.1, Canis lupus ; NP_001073048.1, Bos taurus ; NP_112544.1, Mus musculus ; XP_217335.3, Rattus norvegicus ; and NP_001032921.1, Gallus gallus.

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

References

Correspondence

CME
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Related Topics
PubMed Articles
Jobs